Physician profile
Rivkah E Raza
NPI 1063827384
$4,273.92
in general payments reported to CMS, 2019-2025
24 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,084 · 2020: $587 · 2021: $501 · 2022: $637 · 2023: $543 · 2024: $464 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,450 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.79 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $581.81 | 2019-2024 | |
| Lilly USA, LLC | $438.81 | 2019-2024 | Zepbound, Jardiance, Mounjaro |
| Abbvie INC. | $426.00 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $416.14 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $415.56 | 2019-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $375.43 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $301.11 | 2019-2025 | |
| Glaxosmithkline, LLC. | $229.60 | 2019-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Merck Sharp & Dohme LLC | $201.67 | 2019-2025 | Gardasil 9, Capvaxive |
| Amarin Pharma, INC. | $170.50 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $130.98 | 2019-2022 | |
| Astellas Pharma US INC | $127.03 | 2021-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $109.85 | 2020-2025 | Trintellix |
| Allergan, INC. | $66.65 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $59.53 | 2020-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $36.53 | 2020-2021 | |
| Redhill Biopharma INC. | $34.52 | 2022 | |
| Alkermes, INC. | $33.91 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.39 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $23.30 | 2019 | |
| Hikma Pharmaceuticals USA | $22.51 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.25 | 2022 | |
| Neos Therapeutics, Lp | $14.79 | 2023 | Adzenys Xr-Odt |
| Teva Pharmaceuticals USA, INC. | $12.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rivkah Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.